<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genomics</journal-id><journal-title>BMC Medical Genomics</journal-title><issn pub-type="epub">1755-8794</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1755-8794-1-25</article-id><article-id pub-id-type="pmid">18549475</article-id><article-id pub-id-type="doi">10.1186/1755-8794-1-25</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Blons</surname><given-names>H&#x000e9;l&#x000e8;ne</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>helene.blons@univ-paris5.fr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Pallier</surname><given-names>Karine</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>karine.pallier@univ-paris5.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Le Corre</surname><given-names>Delphine</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>delphine.lecorre@univ-paris5.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Danel</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>claire.danel@bch.aphp.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Tremblay-Gravel</surname><given-names>Maxime</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>maxime.tremblay-gravel@umontreal.ca</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Houdayer</surname><given-names>Claude</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>claude.houdayer@curie.net</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Fabre-Guillevin</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>elizabeth.fabre-guillevin@egp.ap-hop-paris.fr</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Riquet</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I7">7</xref><email>marc.riquet@egp.ap-hop-paris.fr</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Dessen</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>dessen@igr.fr</email></contrib><contrib id="A10" corresp="yes" contrib-type="author"><name><surname>Laurent-Puig</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>pierre.laurent-puig@univ-paris5.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>UMR-S775, INSERM, Paris, F-75006, France</aff><aff id="I2"><label>2</label>Universit&#x000e9; Paris Descartes, Paris, F-75006, France</aff><aff id="I3"><label>3</label>Department of Biology, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, AP-HP, Paris, F-75015, France</aff><aff id="I4"><label>4</label>Department of Pathology, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, AP-HP, Paris, F-75015, France</aff><aff id="I5"><label>5</label>Department of Molecular Oncology, Institut Curie, Paris, F-75005, France</aff><aff id="I6"><label>6</label>Department of Oncology, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, AP-HP, Paris, F-75015, France</aff><aff id="I7"><label>7</label>Department of Thoracic Surgery, H&#x000f4;pital Europ&#x000e9;en Georges Pompidou, AP-HP, Paris, F-75015, France</aff><aff id="I8"><label>8</label>Department of Informatics, Institut Gustave Roussy, Villejuif, F-94905, France</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2008</year></pub-date><volume>1</volume><fpage>25</fpage><lpage>25</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1755-8794/1/25"/><history><date date-type="received"><day>18</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Blons et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Blons et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Blons H&#x000e9;l&#x000e8;ne helene.blons@univ-paris5.fr </dc:author><dc:title> Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Medical Genomics 1(1): 25-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1755-8794(2008)1:1&#x0003c;25&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1755-8794</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Lung cancer with EGFR mutation was shown to be a specific clinical entity. In order to better understand the biology behind this disease we used a genome wide characterization of loss of heterozygosity and amplification by Single Nucleotide Polymorphism (SNP) Array analysis to point out chromosome segments linked to <italic>EGFR </italic>mutations. To do so, we compared genetic profiles between <italic>EGFR </italic>mutated adenocarcinomas (ADC) and <italic>KRAS </italic>mutated ADC from 24 women with localized lung cancer.</p></sec><sec><title>Results</title><p>Patterns of alterations were different between <italic>EGFR </italic>and <italic>KRAS </italic>mutated tumors and specific chromosomes alterations were linked to the <italic>EGFR </italic>mutated group. Indeed chromosome regions 14q21.3 (p = 0.027), 7p21.3-p21.2 (p = 0.032), 7p21.3 (p = 0.042) and 7p21.2-7p15.3 (p = 0.043) were found significantly amplified in EGFR mutated tumors. Within those regions 3 genes are of special interest <italic>ITGB8</italic>, <italic>HDAC9 </italic>and <italic>TWIST1</italic>. Moreover, homozygous deletions at <italic>CDKN2A </italic>and LOH at <italic>RB1 </italic>were identified in <italic>EGFR </italic>mutated tumors. We therefore tested the existence of a link between EGFR mutation, CDKN2A homozygous deletion and cyclin amplification in a larger series of tumors. Indeed, in a series of non-small-cell lung carcinoma (n = 98) we showed that homozygous deletions at <italic>CDKN2A </italic>were linked to <italic>EGFR </italic>mutations and absence of smoking whereas cyclin amplifications (<italic>CCNE1 </italic>and <italic>CCND1</italic>) were associated to <italic>TP53 </italic>mutations and smoking habit.</p></sec><sec><title>Conclusion</title><p>All together, our results show that genome wide patterns of alteration differ between <italic>EGFR </italic>and <italic>KRAS </italic>mutated lung ADC, describe two models of oncogenic cooperation involving either <italic>EGFR </italic>mutation and <italic>CDKN2A </italic>deletion or cyclin amplification and <italic>TP53 </italic>inactivating mutations and identified new chromosome regions at 7p and 14q associated to EGFR mutations in lung cancer.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Lung cancer is the leading cause of cancer-related deaths in the western world [<xref ref-type="bibr" rid="B1">1</xref>]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of the cases and represents a heterogeneous group mainly consisting of adenocarcinoma (ADC), large cell carcinoma (LCC) and squamous cell carcinoma (SCC). The incidence of subtypes has changed in the last decades with increasing incidence of ADC. Moreover, while smoking remains the major risk factor for lung cancer, a subgroup of patients develop lung ADC without smoking history. It is not clear whether lung cancer in non-smokers is increasing in western countries but it is obvious that it has particular clinical and biological features. Population based studies showed that lung cancer in non-smokers occurs preferentially in women with almost 20% of non-smoker lung cancer diagnosed in women versus 2.5% in men [<xref ref-type="bibr" rid="B2">2</xref>]. Different studies have shown that genetic abnormalities can be specifically identified in cancer from non-smokers. Indeed we and others showed that <italic>KRAS </italic>mutations were linked to tobacco consumption whereas EGF receptor <italic>(EGFR) </italic>mutations were found in non smokers [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. The development of EGFR targeted therapies demonstrated that patients with major clinical response were those that had never smoked, had ADC with bronchioloalveolar component, were women and had <italic>EGFR </italic>mutations [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. The biology underlying the pathogenesis of the disease may be different from that of smokers and risk factors have not been clearly identified although environmental etiologies are suspected especially in Asians [<xref ref-type="bibr" rid="B9">9</xref>]. Transformation of a normal phenotype into a malignant phenotype requires accumulation of multiple genetic and-or epigenetic changes resulting in growth advantage.</p><p>The genetic alteration proved to be linked with ADC from non-smokers is the presence of <italic>EGFR </italic>activating mutations. In order to improve our knowledge of lung cancer biology in non-smokers, one of the first questions to answer is: what are the molecular alterations associated to <italic>EGFR </italic>mutations in lung cancer?</p><p>Lung cancer develops as a result of multiple genetic alterations. Loss of heterozygosity (LOH) and gains of chromosome segments are common mechanisms of disease progression. Recently, high-density oligonucleotide-based single polymorphism have been used to quantify chromosome copy number and has been proved to be efficient [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. In an attempt to identify genetic alterations associated with <italic>EGFR </italic>mutations, we used genome wide SNP assay covering 50000 SNP loci to screen for regions of allelic imbalance (amplified or LOH regions) in a panel of 13 <italic>EGFR </italic>mutated ADC and 11 non-<italic>EGFR </italic>mutated ADC.</p><p>Then, in a second part, we focused on cell cycle genes that were found to be differentially involved between groups and screened a large series of 98 NSCLC for genetic alterations at <italic>CCND1</italic>, <italic>CCNE1</italic>, <italic>CDKN2A </italic>and <italic>RB1</italic>. Alterations were studied according to other known mutations (<italic>EGFR</italic>, <italic>ERBB2</italic>, <italic>BRAF</italic>, <italic>KRAS</italic>, <italic>TP53 </italic>and <italic>STK11</italic>). This work led to the characterization of two different models of oncogenic cooperation one linked to smoking and the other not. Moreover, we identified four chromosome regions at 14q and 7p specifically amplified in EGFR mutated ADC.</p></sec><sec sec-type="methods"><title>Patients and methods</title><p>Patients with primary lung cancers were enrolled in this study according to French laws and have been previously described [<xref ref-type="bibr" rid="B4">4</xref>]. Briefly, patients had surgery for non-small cell lung cancer, no neoadjuvant treatment and were managed to the Georges Pompidou European Hospital in Paris, France from 2003 to 2004. All tumors but numbers 134, 135, 177 and 246 had been characterized for mutations in <italic>EGFR</italic>, <italic>KRAS</italic>, <italic>BRAF</italic>, <italic>ERBB2</italic>, <italic>ERBB3</italic>, <italic>PIK3CA</italic>, <italic>TP53 </italic>and <italic>STK11 </italic>[<xref ref-type="bibr" rid="B4">4</xref>]. <italic>STK11 </italic>mutations have not been previously published. Patient characteristics are summarized in Table <xref ref-type="table" rid="T3">3</xref>. DNAs were extracted after pulverization in liquid nitrogen and protein kinase digestion using Qiamp tissue kit (Qiagen, Les Ulis, France). Twenty-four DNAs (13 with classic <italic>EGFR </italic>mutations, 11 without) and 6 non-tumor DNAs were selected for SNP array analysis. All tumors selected were from women.</p><sec><title>Single Nucleotide Polymorphism Array Analysis</title><p>Genechip<sup>&#x000ae; </sup>Mapping 50K-Xba array was used for this analysis. Preparation of DNA targets, labelling, hybridization, washing, staining and scanning was done according to the manufacturer's instructions (Affymetrix, UK) by PartnerChip (Evry, France).</p><p>Data were analyzed using Copy Number Analyser for Affymetrix Gene Chip Mapping (CNAG 2.0) software [<xref ref-type="bibr" rid="B13">13</xref>]. We selected randomly 18 independent subjects from Mapping 100k HapMap Trio Dataset provided by affymetrix. Indeed, this software/algorithm uses a set of normal reference individuals and do not require the use of a paired normal sample to perform the analysis.</p><p>Data from CNAG were export in aCGH sotfware (R package) that was used for plot performance and statistical comparison of <italic>EGFR </italic>mutated and non-mutated tumors.</p></sec><sec><title>Quantitative PCR experiments</title><p>Validation of homozygous deletions (<italic>CDKN2A</italic>) and regions with focal amplification (<italic>CCND1 </italic>and <italic>CCNE1</italic>) was done on the 24 tumors screened by SNP array and extended to a total of 98 NSCLC (Table <xref ref-type="table" rid="T2">2</xref>). Human serum albumin (<italic>HSA</italic>) was used as the reference gene. DNA concentrations were determined using ND-1000 spectrophotometer Nanodrop technology and were normalized to 12,5ng/ul. Real time quantitative PCR using TaqMan probes was performed using an ABI Prism 7900 sequence detection system (Applied Biosystems, Courtaboeuf, France) with the software program SDS 2.0 (Applied Biosystems). Each assay was run on a 384 plate, tumor DNAs, normal controls (n = 6) and no template controls were run in triplicates for <italic>CCND1</italic>, <italic>CCNE1</italic>, <italic>CDKN2A </italic>and <italic>HSA</italic>. Primers and probes were described elsewhere [<xref ref-type="bibr" rid="B14">14</xref>]. Homozygous deletions at <italic>DCC</italic>, <italic>DSG2 </italic>and <italic>DSC3 </italic>as well as copy number changes of the <italic>HDAC9</italic>, <italic>TWIST1 </italic>and <italic>ITGB8 </italic>region were validated by real time PCR for the 24 tumors screened by SNP array. Primers and probes where designed with Primer Express 2.0 software program (Applied Biosystems) (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). All primers were purchased from Operon (Cologne, Germany) and probes from Applied Biosystems.</p><p>The PCR mix consisted of ABsolute&#x02122; QPCR MIX 1&#x000d7; (ABgene, Courtaboeuf, France), primers 300 nM, probe 200 nM, H<sub>2</sub>0 and 25 ng of DNA template in a final volume of 10 ul. Cycling condition were denaturation 95&#x000b0;C for 15 min and 40 cycles of 95&#x000b0;C, 15 sec followed by 60&#x000b0;C, 15 sec. Quantification was done by normalizing the results to those of <italic>HSA</italic>. The normalized amount of gene in tumor samples was determined by designating the average of &#x00394;Ct of 6 non-tumor tissues as calibrator. 2 &#x000d7; 2<sup>-&#x00394;&#x00394;Ct </sup>represented an estimation of the number of gene copy in tumor tissues.</p><p>The cutoff value was 2 &#x000d7; 2<sup>-&#x00394;&#x00394;Ct </sup>&#x02264; 0.6 for homozygous deletion and 2 &#x000d7; 2<sup>-&#x00394;&#x00394;Ct </sup>&#x02265; 4 for amplifications.</p></sec><sec><title><italic>STK11 </italic>Mutations screening</title><p>Exons 1 to 9 were screened by direct sequencing. Primers used for the amplification and sequencing of each exon and intron-exon junctions and PCR conditions are available upon request.</p></sec><sec><title>Statistical analysis</title><p>Fractional allelic loss (FAL) and fractional allelic amplification (FAA) were calculated for each tumor as the number of chromosome arms with either loss of heterozygosity or amplifications divided by the number of chromosome arms tested (41). Mean FAL and FAA were compared using student T test. Qualitative variables were compared using chi square test or Fisher exact test when necessary. All tests were performed using STATA 7.0 (StataCorp LP, College Station, TX) aCGH software was used to test the existence of meaningful differences between focal chromosome alterations in <italic>EGFR </italic>mutated and non-mutated tumors. False discovery rate test (FDR) has been used to assess p values. FDR represents the expected percentage of false positive among the claimed positive and estimates global error for multiple testing situations. Therefore p values were adjusted to the number of tests performed.</p></sec></sec><sec><title>Results</title><sec><title>Array global analysis</title><p>Mapping genome wide chromosomal alterations in <italic>EGFR </italic>mutated lung ADC (n = 13) versus non-mutated ones (n = 11) had two different objectives. First, a global comparison of allelic imbalances and second, a targeted analysis of specific loci to point out genes implicated in the oncogenesis of one subtype or the other. It is to note that, in an effort to homogenize both groups, non-EGFR mutated ADC are all <italic>KRAS </italic>mutated. Fractional allelic loss (FAL) and fractional allelic amplification (FAA) were calculated as the number of chromosome arm with LOH or amplified loci divided by 41 chromosome arms.</p><p>Mean FALs were equal to 0.16 (&#x000b1; 0.08) and 0.09 (&#x000b1; 0.05), (p = 0.024) in the <italic>EGFR </italic>and the <italic>KRAS </italic>mutated group respectively. Chromosome arms that were involved in LOH (copy number &#x02264; 1) in more than 25% of tumors were, in the <italic>EGFR </italic>mutated group 6q, 7q, 8p, 9p, 10q, 12p, 12q, 13q, 15q and 18q, and in the <italic>KRAS </italic>mutated group 3q, 5q, 8p and 19p. A single copy of chromosome 9, 13, 15, 18 and 22 was found in at least one <italic>EGFR </italic>tumor, no monosomy was found in the <italic>KRAS </italic>group (Figure <xref ref-type="fig" rid="F1">1a</xref> and <xref ref-type="fig" rid="F1">1b</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>DNA copy number alterations by SNP array analysis. </bold> Figure 1 represents the fraction of the samples with copy number amplification of at least three copies (green) and copy number reduction (red) across all chromosome SNPs; in the EGFR non-mutated/KRAS mutated group (A) and the EGFR mutated/ KRAS non-mutated group (B). (C) Statistical comparison of both groups showing regions of amplification 20 statistically linked to EGFR mutated tumors (black arrows). False discovery rate (FDR) has been used to estimate global error for multiple testing situations.</p></caption><graphic xlink:href="1755-8794-1-25-1"/></fig><p>Concerning amplifications, mean FAAs were equal to 0.50 (&#x000b1; 0.19) and 0.33 (&#x000b1; 0.24), (p = 0.039) in the <italic>EGFR </italic>versus the <italic>KRAS </italic>mutated group. Chromosome that had amplified regions (copy number &#x02265; 3) at high rates (&#x0003e; 50% of tumors) were 1p-q, 2p, 3q, 5q, 7p-q, 8q, 14q, 17q, 21q and Xp-q in the <italic>EGFR </italic>mutated group and 1q, 2p-q, 5p, 8q and Xp-q in the <italic>KRAS </italic>mutated group (Figure <xref ref-type="fig" rid="F1">1a</xref> and <xref ref-type="fig" rid="F1">1b</xref>).</p></sec><sec><title>Array targeted analysis</title><p>Differential analysis between <italic>EGFR </italic>mutated and <italic>KRAS </italic>mutated tumors using aCGH package [<xref ref-type="bibr" rid="B15">15</xref>] showed that one region at 14q (p = 0.027) and three regions at 7p (p = 0.032, p = 0.042, p = 0.043) were statistically more frequently amplified in the <italic>EGFR </italic>group (Figure <xref ref-type="fig" rid="F1">1c</xref>). Detailed statistic analysis is shown as supplementary data (see Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>). Genes located in these regions are given in Table <xref ref-type="table" rid="T1">1</xref>. The gene located at 14q is a MAM domain protein. The MAM domain is present in many cell surface proteins and is thought to be involved in cell-cell adhesion, protein-protein interactions, and signal transduction, whether this protein could be linked to carcinogenesis remain to be studied [<xref ref-type="bibr" rid="B16">16</xref>]. Of the ones located at 7p21.1, it is to note that <italic>HDAC9, TWIST1 </italic>and <italic>ITGB8 </italic>are potential targets. Gene copy numbers at 7p21.1 were validated by quantitative PCR using probes <italic>HDAC9 </italic>and <italic>ITGB8 </italic>in the 24 tumors and 7 cell lines were tested for copy number changes using same probes (Calu6-H460-A549-H1299-H1650-H1975-H358), both cell lines with <italic>EGFR </italic>mutation were found amplified (H1650-H1975) versus one out of five without EGFR mutations (H358). <italic>EGFR </italic>is located at 7p11.2, among tumors with <italic>EGFR </italic>mutations, one has no copy number alteration at 7p, 9 showed concomitant 7p11.2 and 7p21.1 amplifications (&#x0003e;3) and 3 had a localized amplification, 2 at 7p21.1 and 1 at 7p11.2. EGFR amplifications were not statistically related with EGFR mutation but 5/13 in the EGFR group versus 1/11 in the KRAS group had estimated copy number &#x0003e; 4.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Shows regions of focal amplifications analyzed by Xba1 50000 SNPs array (Affymetrix) that are significantly linked to EGFR mutated tumors.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Base position start</bold></td><td align="center"><bold>Base position end</bold></td><td align="center"><bold>Chromosome Band</bold></td><td align="center"><bold>Genes within the region</bold></td><td align="center"><bold>NAME</bold></td><td align="center"><bold>Known functions</bold></td></tr></thead><tbody><tr><td align="center">46489396</td><td align="center">47088012</td><td align="center">14q21.3</td><td align="center">MAMDC1</td><td align="center">MAM DOMAIN CONTAINING1</td><td align="center">MAM domain containing protein</td></tr><tr><td align="center">11727815</td><td align="center">13456320</td><td align="center">7p21.3-7p21.2</td><td align="center">TMEM106B</td><td align="center">Hypothetical transmembrane protein</td><td align="center">unknown</td></tr><tr><td></td><td></td><td></td><td align="center">AK027618</td><td align="center">Weakly similar to neurogenic locus notch3 protein</td><td align="center">unknown</td></tr><tr><td></td><td></td><td></td><td align="center">AK075525</td><td align="center">Weakly similar to UROMODULIN PRECURSOR</td><td align="center">unknown</td></tr><tr><td></td><td></td><td></td><td align="center">BC075797</td><td align="center">cDNA clone MGC:87550</td><td align="center">unknown</td></tr><tr><td></td><td></td><td></td><td align="center">CR592342</td><td align="center">cDNA clone MGC:87550</td><td></td></tr><tr><td></td><td></td><td></td><td align="center">SCIN</td><td align="center">SCINDERIN</td><td align="center">Organization of microfilament network</td></tr><tr><td></td><td></td><td></td><td align="center">ARL4</td><td align="center">ADP-ribosylation factor-like 4A</td><td align="center">ADP-ribosylation factor family of GTP-binding protein</td></tr><tr><td align="center">11120441</td><td align="center">11377580</td><td align="center">7p21.3</td><td align="center">PHF14</td><td align="center">HD finger protein 14 isoform 1</td><td align="center">unknown</td></tr><tr><td></td><td></td><td></td><td align="center">BC040327</td><td align="center">Homo sapiens cDNA clone IMAGE:4830466</td><td align="center">unknown</td></tr><tr><td align="center">18006698</td><td align="center">20386036</td><td align="center">7p21.1-7p15.3</td><td align="center">PRPS1L1</td><td align="center">PRPS1L1</td><td align="center">Phosphoribosyl pyrophosphate synthetase 1-like</td></tr><tr><td></td><td></td><td></td><td align="center">HDAC9</td><td align="center">Histone deacetylase 9 isoform 4</td><td align="center">Histone acetylation/deacetylation alters chromosome structure and affects transcription factor access to DNA</td></tr><tr><td></td><td></td><td></td><td align="center">TWIST1</td><td align="center">TWIST1</td><td align="center">The protein encoded by this gene is a bHLH transcription factor. Basic helix-loop-helix (bHLH) transcription factors have been implicated in cell lineage determination and differentiation.</td></tr><tr><td></td><td></td><td></td><td align="center">FERD3L</td><td align="center">Nephew of atonal 3</td><td align="center">N-TWIST basic (helix-loop-helix protein)</td></tr><tr><td></td><td></td><td></td><td align="center">TWISTNB</td><td align="center">TWIST neighbor</td><td align="center">DNA-directed RNA polymerase I subunit RPA43-transcription</td></tr><tr><td></td><td></td><td></td><td align="center">MGC42090</td><td align="center">Hypothetical protein LOC256130</td><td align="center">unknown</td></tr><tr><td></td><td></td><td></td><td align="center">7A5</td><td align="center">Putative binding protein 7a5</td><td align="center">unknown</td></tr><tr><td></td><td></td><td></td><td align="center">ITGB8</td><td align="center">integrin, beta 8 precursor</td><td align="center">This gene is a member of the integrin beta chain family. Integrin complexes mediate cell-cell and cell-extracellular matrix interactions and this complex plays a role in human airway epithelial proliferation.</td></tr></tbody></table></table-wrap><p>Regardless of statistical difference between the two groups, focal amplifications and homozygous deletion are of special interest as they may indicate oncogenes or tumor suppressors. Recurrent regions of deletions and focal amplifications were defined as segments of at least 5 SNP loci in more than 2 tumors.</p><p>A total of 58 regions with focal amplification were identified. Among them 22 regions were found exclusively in <italic>EGFR </italic>mutated tumors versus 2 in <italic>KRAS </italic>mutated tumors. Genes potentially involved in carcinogenesis located in these regions are listed as supplementary material (see Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>), <italic>AFF3</italic>, <italic>LAF4</italic>, <italic>LRRC1</italic>, <italic>SNW1</italic>, <italic>FGF7</italic>, <italic>PPL </italic>and <italic>CTAGE1 </italic>for <italic>EGFR </italic>mutated tumors and <italic>MYST3</italic>, <italic>IKBKB</italic>, <italic>DKK4 </italic>for <italic>KRAS </italic>mutated tumors. Regions of amplifications common to both groups delineated by the SNP array included <italic>BCL9</italic>, <italic>FGF10</italic>, <italic>IL31RA</italic>, <italic>PLK2</italic>, <italic>WISP1</italic>, <italic>HTERT</italic>, <italic>CCND3</italic>, <italic>EFGR</italic>, <italic>MYC</italic>.</p><p>Homozygous deletions were identified at chromosome regions 2q36.3, 9p21.1, 12q13.13, 18q12.1 and 18q21.2. The 9p21.1 locus contains <italic>CDKN2A </italic>and the 18q21.1 contains <italic>DCC</italic>, both are well known tumor suppressors. Genes in the 12q13.13 and 2q36.3 regions have not been linked to cancer up to now and the 18q12.1 region contains a cluster of genes coding desmosomal proteins. All homozygous deletions were found in the <italic>EGFR </italic>mutated group (Table <xref ref-type="table" rid="T2">2</xref>). For the 24 tumors, quantitative PCR was ran to estimated gene copy number at <italic>CDKN2A</italic>, <italic>DSG3</italic>, <italic>DSC2 </italic>and <italic>DCC </italic>and validated the results of the SNP Array (see Additional file <xref ref-type="supplementary-material" rid="S4">4</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Regions of homozygous deletions identified by SNP array in this series. </p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>CHR</bold></td><td align="center"><bold>CYTOBAND</bold></td><td align="center"><bold>Deletion START</bold></td><td align="center"><bold>Deletion END</bold></td><td align="center"><bold>No OF T WITHOUT EGFR MUT</bold></td><td align="center"><bold>No OF T WITH EGFR MUT</bold></td><td align="center"><bold>KNOWN GENES WITHIN REGIONS</bold></td><td align="center"><bold>GENES</bold></td><td></td><td></td></tr></thead><tbody><tr><td align="center">2</td><td align="center">2q36.3</td><td align="center">227428860</td><td align="center">228480608</td><td align="center">0</td><td align="center">2(1LOH+1HOMO)</td><td align="center">3</td><td align="center">RHBDD1</td><td align="center">COL4A4</td><td align="center">COL4A3</td></tr><tr><td align="center">9</td><td align="center">9p21.1</td><td align="center">21701815</td><td align="center">22685593</td><td align="center">2 (LOH)</td><td align="center">7(4LOH+3HOMO)</td><td align="center">3</td><td align="center"><bold>CDKN2A/2B</bold></td><td align="center">MTAP</td><td align="center">DMRTA1</td></tr><tr><td align="center">12</td><td align="center">12q13.13</td><td align="center">49778776</td><td align="center">50467951</td><td align="center">1(LOH)</td><td align="center">1HOMO</td><td align="center">3</td><td align="center">TFCP2</td><td align="center">POU6F1</td><td align="center">DAZAP2</td></tr><tr><td align="center">18</td><td align="center">18q12.1</td><td align="center">25534701</td><td align="center">27580619</td><td align="center">2(LOH)</td><td align="center">3(2LOH+1HOMO)</td><td align="center">3</td><td align="center">CDH2</td><td align="center"><bold>DSC3</bold></td><td align="center"><bold>DSG2</bold></td></tr><tr><td align="center">18</td><td align="center">18q21.2</td><td align="center">46939466</td><td align="center">49883403</td><td align="center">2(LOH)</td><td align="center">4(3LOH+1HOMO)</td><td align="center">2</td><td align="center">RKHD2</td><td align="center"><bold>DCC</bold></td><td></td></tr></tbody></table><table-wrap-foot><p>Homozygous deletion were validated by real time quantitative PCR for CDKN2A, DCC, DSC3 and DSG2.</p></table-wrap-foot></table-wrap></sec><sec><title>Cell cycle related genes and lung carcinogenesis</title><p>The presence of <italic>CDKN2A </italic>homozygous deletion was restricted to the <italic>EGFR </italic>group and concerned 3 tumors out of 13 while LOH at this locus was present in 4 <italic>EGFR </italic>mutated tumors versus 2 non-mutated ones. Furthermore, since LOH at <italic>RB1 </italic>was restricted to <italic>EGFR </italic>mutated tumors we made the hypothesis that alterations of the G1-S check point could be different in <italic>EGFR </italic>mutated tumors as compared to non-mutated ones. Differences at <italic>CDKN2A </italic>and <italic>RB1 </italic>did not reach statistical significance at the array level however it deserved to be confirmed in a larger series of NSCLC and enlarge to other key regulators as cyclins. LOH at <italic>RB1 </italic>locus clustered to the <italic>EGFR </italic>group, therefore we screened the entire coding sequence and exon-intron boundaries for alterations in the subgroup of 13 <italic>EGFR </italic>mutated tumors. As no mutation was identified in this subgroup of tumors, <italic>RB1 </italic>sequencing was not done on the entire series. Then, <italic>CDKN2A </italic>homozygous deletions, <italic>CCNE1 </italic>and <italic>CCND1 </italic>amplifications were analyzed by real time quantitative PCR on a series of 98 NSCLC including the 24 tumors previously typed by SNP array. All tumors had been characterized for <italic>EGFR</italic>, <italic>ERBB2</italic>, <italic>PIK3CA</italic>, <italic>BRAF</italic>, <italic>KRAS </italic>and <italic>STK11 </italic>mutations. Briefly, 13 and 6 NSCLC had <italic>CCND1 </italic>or <italic>CCNE1 </italic>amplification respectively and 8 tumors had homozygous deletion at <italic>CDKN2A </italic>locus including the 3 previously found in array analysis (Table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Describes the population studied in terms of clinico-pathological features, gene mutations (EGFR, ERBB2, PIK3CA, KRAS, BRAF and TP53) as well as gene copy number (CCND1, CCNE1 and CDKN2A) analyzed by real time PCR. </p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>N&#x000b0;</bold></td><td align="center"><bold>Sex</bold></td><td align="center"><bold>Age at diagnosis</bold></td><td align="center"><bold>Smoker</bold></td><td align="center"><bold>TNM</bold></td><td align="center"><bold>Tumor Type</bold></td><td align="center"><bold>EGFR</bold></td><td align="center"><bold>TP53</bold></td><td align="center"><bold>KRAS</bold></td><td align="center"><bold>ERBB2</bold></td><td align="center"><bold>PIK3CA</bold></td><td align="center"><bold>STK11</bold></td><td align="center"><bold>CCND (2*2-DDCt)</bold></td><td align="center"><bold>CCNE1 (2*2-DDCt)</bold></td><td align="center"><bold>CDKN2A (2*2-DDCt)</bold></td></tr></thead><tbody><tr><td align="center">2</td><td align="center">F</td><td align="center">49</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">BAC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">c650insG, pFs265X</td><td align="center">2,42</td><td align="center">2.32</td><td align="center">0.53</td></tr><tr><td align="center">3</td><td align="center">F</td><td align="center">61</td><td align="center">Yes</td><td align="center">T3N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2,70</td><td align="center">2.30</td><td align="center">0.82</td></tr><tr><td align="center"><underline>4</underline></td><td align="center">F</td><td align="center">42</td><td align="center">Yes</td><td align="center">T1N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">C743G&#x0003e;T, pR248L</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1,86</td><td align="center">3.38</td><td align="center">1.03</td></tr><tr><td align="center">5</td><td align="center">F</td><td align="center">80</td><td align="center">No</td><td align="center">T4N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1,82</td><td align="center">2.05</td><td align="center">0.90</td></tr><tr><td align="center">6</td><td align="center">F</td><td align="center">41</td><td align="center">Yes</td><td align="center">T2N2</td><td align="center">LCC</td><td align="center">0</td><td align="center">c358A&#x0003e;T, pK120X</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3,16</td><td align="center">2.19</td><td align="center">2.38</td></tr><tr><td align="center">7</td><td align="center">F</td><td align="center">39</td><td align="center">Yes</td><td align="center">T2Nx</td><td align="center">LCC</td><td align="center">0</td><td align="center">c796G&#x0003e;T, pL266X</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">c153delG, pFs63X</td><td align="center">3,13</td><td align="center">2.36</td><td align="center">3.42</td></tr><tr><td align="center">8</td><td align="center">F</td><td align="center">69</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.68</td><td align="center">2.36</td><td align="center">0.71</td></tr><tr><td align="center">9</td><td align="center">F</td><td align="center">65</td><td align="center">No</td><td align="center">T2N1</td><td align="center">ADC</td><td align="center">0</td><td align="center">c452454del, FsP153G</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.92</td><td align="center">2.44</td><td align="center">1.17</td></tr><tr><td align="center">10</td><td align="center">F</td><td align="center">79</td><td align="center">No</td><td align="center">T4N0</td><td align="center">ADC/BAC</td><td align="center">L858R</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.68</td><td align="center">2.92</td><td align="center">0.33</td></tr><tr><td align="center"><underline>12</underline></td><td align="center">F</td><td align="center">52</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">0</td><td align="center">c35G&#x0003e;A pG12D</td><td align="center">0</td><td align="center">0</td><td align="center">C508C&#x0003e;T, pQ170X</td><td align="center">1.71</td><td align="center">1.43</td><td align="center">1.05</td></tr><tr><td align="center">13</td><td align="center">F</td><td align="center">77</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.28</td><td align="center">2.26</td><td align="center">1.22</td></tr><tr><td align="center"><underline>15</underline></td><td align="center">F</td><td align="center">73</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">BAC</td><td align="center">0</td><td align="center">0</td><td align="center">c35G&#x0003e;T pG12V</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.75</td><td align="center">2.16</td><td align="center">0.72</td></tr><tr><td align="center">16</td><td align="center">F</td><td align="center">46</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">c614A&#x0003e;G, pY205C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">4.59</td><td align="center">2.66</td><td align="center">1.90</td></tr><tr><td align="center"><underline>17</underline></td><td align="center">F</td><td align="center">84</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">L858R</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.84</td><td align="center">1.97</td><td align="center">0.90</td></tr><tr><td align="center"><underline>18</underline></td><td align="center">F</td><td align="center">65</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">c2241_2258del p747-753del insQ747</td><td align="center">c880delG, FsE294S</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.22</td><td align="center">2.51</td><td align="center">2.18</td></tr><tr><td align="center"><underline>21</underline></td><td align="center">F</td><td align="center">50</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">0</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.15</td><td align="center">2.75</td><td align="center">1.73</td></tr><tr><td align="center">22</td><td align="center">F</td><td align="center">78</td><td align="center">Yes</td><td align="center">T2N1</td><td align="center">LCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">c595G&#x0003e;C, pE198Q</td><td align="center">4.64</td><td align="center">3.05</td><td align="center">1.23</td></tr><tr><td align="center">23</td><td align="center">F</td><td align="center">49</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">LCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">c1072C&#x0003e;Q, pF354L</td><td align="center">2.90</td><td align="center">2.37</td><td align="center">0.96</td></tr><tr><td align="center"><underline>24</underline></td><td align="center">F</td><td align="center">65</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">BAC</td><td align="center">0</td><td align="center">c574C&#x0003e;T, PQ192X</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.82</td><td align="center">2.34</td><td align="center">1.77</td></tr><tr><td align="center">25</td><td align="center">F</td><td align="center">55</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.84</td><td align="center">1.81</td><td align="center">1.51</td></tr><tr><td align="center">26</td><td align="center">F</td><td align="center">73</td><td align="center">No</td><td align="center">T2N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">c783-2A&#x0003e;G, SLPICEMUT</td><td align="center">0</td><td align="center">c2322_2323ins12, pM774_A775ins AYVM</td><td align="center">0</td><td align="center">0</td><td align="center">2.60</td><td align="center">3.56</td><td align="center">1.68</td></tr><tr><td align="center"><underline>29</underline></td><td align="center">F</td><td align="center">61</td><td align="center">No</td><td align="center">T2N1</td><td align="center">ADC</td><td align="center">L858R</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.98</td><td align="center">2.06</td><td align="center">0.29</td></tr><tr><td align="center"><underline>30</underline></td><td align="center">F</td><td align="center">59</td><td align="center">No</td><td align="center">T4N2</td><td align="center">ADC</td><td align="center">L858R</td><td align="center">c258-280del, FsA86A</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.31</td><td align="center">1.47</td><td align="center">0.59</td></tr><tr><td align="center"><underline>31</underline></td><td align="center">F</td><td align="center">75</td><td align="center">No</td><td align="center">T2N2</td><td align="center">ADC</td><td align="center">c2240_2257del, p747-753del insS747</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.08</td><td align="center">2.31</td><td align="center">1.02</td></tr><tr><td align="center">32</td><td align="center">F</td><td align="center">68</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">c848G&#x0003e;C, pR283P</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">4.44</td><td align="center">3.52</td><td align="center">1.75</td></tr><tr><td align="center">34</td><td align="center">F</td><td align="center">59</td><td align="center">Yes</td><td align="center">T2N2</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">5.62</td><td align="center">2.21</td><td align="center">1.31</td></tr><tr><td align="center">36</td><td align="center">F</td><td align="center">70</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.87</td><td align="center">2.24</td><td align="center">1.21</td></tr><tr><td align="center">37</td><td align="center">F</td><td align="center">72</td><td align="center">Yes</td><td align="center">T1NO</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.17</td><td align="center">2.00</td><td align="center">1.62</td></tr><tr><td align="center"><underline>38</underline></td><td align="center">F</td><td align="center">60</td><td align="center">Yes</td><td align="center">T2N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">c747G&#x0003e;T, pR249S</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.41</td><td align="center">2.48</td><td align="center">0.81</td></tr><tr><td align="center"><underline>39</underline></td><td align="center">F</td><td align="center">75</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">L858R</td><td align="center">c189G&#x0003e;T, pE62X</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0.91</td><td align="center">2.04</td><td align="center">0.92</td></tr><tr><td align="center"><underline>41</underline></td><td align="center">F</td><td align="center">56</td><td align="center">No</td><td align="center">T1NO</td><td align="center">ADC/BAC</td><td align="center">L858R</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.58</td><td align="center">3.08</td><td align="center">1.29</td></tr><tr><td align="center"><underline>42</underline></td><td align="center">F</td><td align="center">43</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">c35G&#x0003e;T pG12V</td><td align="center">0</td><td align="center">0</td><td align="center">c580G&#x0003e;T, pD194Y</td><td align="center">1.84</td><td align="center">2.49</td><td align="center">1.01</td></tr><tr><td align="center"><underline>43</underline></td><td align="center">F</td><td align="center">72</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">c2310insAGCGTGGAC p770insSVD</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.11</td><td align="center">2.41</td><td align="center">0.57</td></tr><tr><td align="center">44</td><td align="center">F</td><td align="center">63</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">LCC</td><td align="center">0</td><td align="center">c743G&#x0003e;T, pR248L</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.38</td><td align="center">10.31</td><td align="center">0.74</td></tr><tr><td align="center">45</td><td align="center">F</td><td align="center">60</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">c166G&#x0003e;T, pE56X</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.73</td><td align="center">2.94</td><td align="center">1.03</td></tr><tr><td align="center">46</td><td align="center">F</td><td align="center">57</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.39</td><td align="center">2.67</td><td align="center">0.70</td></tr><tr><td align="center">48</td><td align="center">F</td><td align="center">49</td><td align="center">Yes</td><td align="center">T3N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.58</td><td align="center">2.98</td><td align="center">0.83</td></tr><tr><td align="center"><underline>49</underline></td><td align="center">F</td><td align="center">75</td><td align="center">No</td><td align="center">T2N0</td><td align="center">BAC</td><td align="center">c2237_2255delinsT, p746-752del insV746</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.77</td><td align="center">2.20</td><td align="center">1.58</td></tr><tr><td align="center">50</td><td align="center">F</td><td align="center">42</td><td align="center">Yes</td><td align="center">T3N0</td><td align="center">LCC</td><td align="center">0</td><td align="center">c814G&#x0003e;T, pV272L</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">6.26</td><td align="center">3.13</td><td align="center">2.40</td></tr><tr><td align="center">51</td><td align="center">F</td><td align="center">51</td><td align="center">Yes</td><td align="center">n.d.</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3.52</td><td align="center">3.18</td><td align="center">1.58</td></tr><tr><td align="center">52</td><td align="center">F</td><td align="center">78</td><td align="center">No</td><td align="center">T2N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.77</td><td align="center">2.13</td><td align="center">1.79</td></tr><tr><td align="center"><underline>53</underline></td><td align="center">F</td><td align="center">55</td><td align="center">Yes</td><td align="center">T4NO</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">0</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.79</td><td align="center">2.14</td><td align="center">2.06</td></tr><tr><td align="center"><underline>54</underline></td><td align="center">F</td><td align="center">78</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">c2239_2251delinsC, p747-751delinsP747</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.31</td><td align="center">2.12</td><td align="center">1.90</td></tr><tr><td align="center"><underline>55</underline></td><td align="center">F</td><td align="center">72</td><td align="center">No</td><td align="center">T2N2</td><td align="center">ADC/BAC</td><td align="center">L858R</td><td align="center">COMPLEX INSDEL</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.65</td><td align="center">1.81</td><td align="center">1.72</td></tr><tr><td align="center">57</td><td align="center">M</td><td align="center">85</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.87</td><td align="center">1.94</td><td align="center">1.89</td></tr><tr><td align="center">58</td><td align="center">M</td><td align="center">51</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">c467G&#x0003e;C, pR156P</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.79</td><td align="center">1.96</td><td align="center">1.77</td></tr><tr><td align="center">59</td><td align="center">M</td><td align="center">51</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.10</td><td align="center">1.39</td><td align="center">1.92</td></tr><tr><td align="center">60</td><td align="center">M</td><td align="center">71</td><td align="center">Yes</td><td align="center">T1NO</td><td align="center">SCC</td><td align="center">0</td><td align="center">c-15-96del, Fs mutation</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.85</td><td align="center">1.78</td><td align="center">1.88</td></tr><tr><td align="center">62</td><td align="center">M</td><td align="center">48</td><td align="center">Yes</td><td align="center">T4NO</td><td align="center">ADC</td><td align="center">0</td><td align="center">C783-2A&#x0003e;G, SLPICEMUT</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.80</td><td align="center">2.26</td><td align="center">1.73</td></tr><tr><td align="center">64</td><td align="center">M</td><td align="center">71</td><td align="center">Yes</td><td align="center">T3N1</td><td align="center">ADC</td><td align="center">0</td><td align="center">c466-483del, FsI162H</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.86</td><td align="center">2.12</td><td align="center">0.69</td></tr><tr><td align="center">65</td><td align="center">M</td><td align="center">49</td><td align="center">Yes</td><td align="center">T4NO</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">C817C&#x0003e;T, pR273C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.33</td><td align="center">2.24</td><td align="center">2.02</td></tr><tr><td align="center">66</td><td align="center">M</td><td align="center">56</td><td align="center">Yes</td><td align="center">T2N1</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.88</td><td align="center">1.98</td><td align="center">1.82</td></tr><tr><td align="center">67</td><td align="center">M</td><td align="center">56</td><td align="center">Yes</td><td align="center">n.d.</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3.25</td><td align="center">2.84</td><td align="center">1.93</td></tr><tr><td align="center">68</td><td align="center">M</td><td align="center">58</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">c818G&#x0003e;T, pR273L</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3.26</td><td align="center">1.86</td><td align="center">1.44</td></tr><tr><td align="center">69</td><td align="center">M</td><td align="center">72</td><td align="center">Yes</td><td align="center">T3N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">c610G&#x0003e;T, pE204X</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3.17</td><td align="center">1.55</td><td align="center">2.19</td></tr><tr><td align="center">70</td><td align="center">M</td><td align="center">71</td><td align="center">Yes</td><td align="center">T3N0</td><td></td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.13</td><td align="center">1.74</td><td align="center">1.90</td></tr><tr><td align="center">71</td><td align="center">M</td><td align="center">69</td><td align="center">Yes</td><td align="center">T3N1</td><td align="center">ADC</td><td align="center">0</td><td align="center">C528C&#x0003e;G, pC176W</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.68</td><td align="center">1.59</td><td align="center">1.97</td></tr><tr><td align="center">72</td><td align="center">M</td><td align="center">77</td><td align="center">Yes</td><td align="center">T3N2</td><td align="center">SCC</td><td align="center">0</td><td align="center">c408DELA, FsQ136H</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.67</td><td align="center">2.23</td><td align="center">1.61</td></tr><tr><td align="center">74</td><td align="center">M</td><td align="center">76</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">SCC</td><td align="center">0</td><td align="center">c318G&#x0003e;C, pG105R</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3.28</td><td align="center">3.94</td><td align="center">2.11</td></tr><tr><td align="center">75</td><td align="center">M</td><td align="center">59</td><td align="center">Yes</td><td align="center">T3N2</td><td align="center">SCC</td><td align="center">0</td><td align="center">c797delG, FsG266D</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">4.66</td><td align="center">2.74</td><td align="center">1.44</td></tr><tr><td align="center">76</td><td align="center">M</td><td align="center">48</td><td align="center">Yes</td><td align="center">T3N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">c35G&#x0003e;T pG12V</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.32</td><td align="center">2.92</td><td align="center">1.90</td></tr><tr><td align="center">78</td><td align="center">M</td><td align="center">67</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.42</td><td align="center">1.81</td><td align="center">1.75</td></tr><tr><td align="center">79</td><td align="center">M</td><td align="center">57</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">c818G&#x0003e;T, pR273L</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">4.27</td><td align="center">5.76</td><td align="center">1.69</td></tr><tr><td align="center">80</td><td align="center">M</td><td align="center">58</td><td align="center">Yes</td><td align="center">T1N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">c35G&#x0003e;A pG12D</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">6.36</td><td align="center">1.66</td><td align="center">1.47</td></tr><tr><td align="center">82</td><td align="center">M</td><td align="center">62</td><td align="center">Yes</td><td align="center">T2N1</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.24</td><td align="center">1.88</td><td align="center">1.84</td></tr><tr><td align="center">83</td><td align="center">M</td><td align="center">51</td><td align="center">Yes</td><td align="center">T3N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">C139-140DEL, pFsP47G c844C&#x0003e;T, pR282W</td><td align="center">c34G&#x0003e;C pG12R</td><td align="center">0</td><td align="center">0</td><td align="center">C521A&#x0003e;G, pM174R</td><td align="center">1.87</td><td align="center">2.38</td><td align="center">1.98</td></tr><tr><td align="center">84</td><td align="center">M</td><td align="center">67</td><td align="center">Yes</td><td align="center">T4N2</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.49</td><td align="center">2.19</td><td align="center">1.98</td></tr><tr><td align="center">85</td><td align="center">M</td><td align="center">56</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">C577C&#x0003e;G, pH193D</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.53</td><td align="center">2.56</td><td align="center">2.09</td></tr><tr><td align="center">86</td><td align="center">M</td><td align="center">74</td><td align="center">Yes</td><td align="center">T1NO</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.19</td><td align="center">2.04</td><td align="center">1.84</td></tr><tr><td align="center">87</td><td align="center">M</td><td align="center">52</td><td align="center">Yes</td><td align="center">T2N1</td><td align="center">ADC</td><td align="center">0</td><td align="center">c595G&#x0003e;T, pG199X</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">c126-149del, pFsmutation</td><td align="center">2.38</td><td align="center">2.61</td><td align="center">1.98</td></tr><tr><td align="center">88</td><td align="center">M</td><td align="center">75</td><td align="center">Yes</td><td align="center">T4N1</td><td align="center">SCC</td><td align="center">0</td><td align="center">C586C&#x0003e;T, pR196X</td><td align="center">0</td><td align="center">0</td><td align="center">c1633G&#x0003e;A, pE545K</td><td align="center">0</td><td align="center">2.88</td><td align="center">3.89</td><td align="center">0.28</td></tr><tr><td align="center">89</td><td align="center">M</td><td align="center">83</td><td align="center">Yes</td><td align="center">T4N1</td><td align="center">SCC</td><td align="center">0</td><td align="center">c560-lG&#x0003e;T, SPLICEMUT</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.37</td><td align="center">1.77</td><td align="center">1.73</td></tr><tr><td align="center">92</td><td align="center">M</td><td align="center">83</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.31</td><td align="center">0.66</td><td align="center">1.86</td></tr><tr><td align="center">93</td><td align="center">M</td><td align="center">50</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">n.d.</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3.81</td><td align="center">1.44</td><td align="center">1.72</td></tr><tr><td align="center">94</td><td align="center">M</td><td align="center">73</td><td align="center">Yes</td><td align="center">T3N2</td><td align="center">SCC</td><td align="center">0</td><td align="center">c785G&#x0003e;T, pG262V</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.40</td><td align="center">1.53</td><td align="center">1.31</td></tr><tr><td align="center">95</td><td align="center">M</td><td align="center">64</td><td align="center">Yes</td><td align="center">T2N1</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.40</td><td align="center">2.28</td><td align="center">1.92</td></tr><tr><td align="center">96</td><td align="center">M</td><td align="center">67</td><td align="center">Yes</td><td align="center">T2N2</td><td align="center">SCC</td><td align="center">0</td><td align="center">c438G&#x0003e;A, pW146X</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">4.16</td><td align="center">2.87</td><td align="center">1.71</td></tr><tr><td align="center">97</td><td align="center">M</td><td align="center">81</td><td align="center">Yes</td><td align="center">T4N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">7.44</td><td align="center">2.68</td><td align="center">1.64</td></tr><tr><td align="center">98</td><td align="center">M</td><td align="center">57</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.41</td><td align="center">2.16</td><td align="center">2.13</td></tr><tr><td align="center">99</td><td align="center">M</td><td align="center">69</td><td align="center">Yes</td><td align="center">T2N1</td><td align="center">SCC</td><td align="center">0</td><td align="center">C586C&#x0003e;T, pR196X</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.85</td><td align="center">6.96</td><td align="center">1.14</td></tr><tr><td align="center">100</td><td align="center">M</td><td align="center">74</td><td align="center">Yes</td><td align="center">T3N2</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.69</td><td align="center">2.42</td><td align="center">1.73</td></tr><tr><td align="center">101</td><td align="center">M</td><td align="center">51</td><td align="center">No</td><td align="center">T4N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.44</td><td align="center">1.95</td><td align="center">1.9</td></tr><tr><td align="center">102</td><td align="center">M</td><td align="center">61</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">SCC</td><td align="center">0</td><td align="center">c578A&#x0003e;G, pH193R</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">6.13</td><td align="center">1.94</td><td align="center">1.89</td></tr><tr><td align="center">103</td><td align="center">M</td><td align="center">52</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.42</td><td align="center">1.34</td><td align="center">1.87</td></tr><tr><td align="center">104</td><td align="center">M</td><td align="center">75</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.38</td><td align="center">1.35</td><td align="center">2.18</td></tr><tr><td align="center">105</td><td align="center">M</td><td align="center">71</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">C832DELC, pFsP278L</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">5.13</td><td align="center">2.04</td><td align="center">1.75</td></tr><tr><td align="center">106</td><td align="center">M</td><td align="center">56</td><td align="center">Yes</td><td align="center">n.d.</td><td align="center">SCC</td><td align="center">0</td><td align="center">C906DELG, pFsS303A</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.66</td><td align="center">2.87</td><td align="center">1.71</td></tr><tr><td align="center">107</td><td align="center">M</td><td align="center">54</td><td align="center">Yes</td><td align="center">T1NO</td><td align="center">ADC</td><td align="center">0</td><td align="center">c460G&#x0003e;A, pG154I</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.50</td><td align="center">0.81</td><td align="center">0.55</td></tr><tr><td align="center">108</td><td align="center">M</td><td align="center">57</td><td align="center">Yes</td><td align="center">T3N1</td><td align="center">SCC</td><td align="center">P753L</td><td align="center">C902DELC, pFsP301Q</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">6.91</td><td align="center">1.55</td><td align="center">1.09</td></tr><tr><td align="center">109</td><td align="center">M</td><td align="center">52</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.48</td><td align="center">1.79</td><td align="center">1.65</td></tr><tr><td align="center">110</td><td align="center">M</td><td align="center">75</td><td align="center">Yes</td><td align="center">T1N1</td><td align="center">SCC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">3.11</td><td align="center">1.71</td><td align="center">1.97</td></tr><tr><td align="center">111</td><td align="center">M</td><td align="center">65</td><td align="center">Yes</td><td align="center">T2N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.41</td><td align="center">1.58</td><td align="center">2.00</td></tr><tr><td align="center">112</td><td align="center">M</td><td align="center">51</td><td align="center">Yes</td><td align="center">T1NO</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">c34G&#x0003e;T pG12C c35G&#x0003e;T pG12V</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.65</td><td align="center">2.73</td><td align="center">1.49</td></tr><tr><td align="center"><underline>134</underline></td><td align="center">F</td><td align="center">62</td><td align="center">No</td><td align="center">T2N0</td><td align="center">ADC</td><td align="center">L858R</td><td align="center">c503A&#x0003e;T, pH168L</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.00</td><td align="center">13.47</td><td align="center">2.13</td></tr><tr><td align="center"><underline>135</underline></td><td align="center">F</td><td align="center">72</td><td align="center">No</td><td align="center">T1NO</td><td align="center">BAC</td><td align="center">c2237_2255delinsT, p746-752del insV746</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.31</td><td align="center">1.16</td><td align="center">0.46</td></tr><tr><td align="center"><underline>143</underline></td><td align="center">F</td><td align="center">55</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">0</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">1.99</td><td align="center">2.10</td><td align="center">1.83</td></tr><tr><td align="center"><underline>177</underline></td><td align="center">F</td><td align="center">67</td><td align="center">Yes</td><td align="center">T2N0</td><td align="center">ADC/BAC</td><td align="center">0</td><td align="center">0</td><td align="center">c35G&#x0003e;A pG12D</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.00</td><td align="center">1.94</td><td align="center">1.71</td></tr><tr><td align="center"><underline>246</underline></td><td align="center">F</td><td align="center">44</td><td align="center">Yes</td><td align="center">T2N2</td><td align="center">ADC</td><td align="center">0</td><td align="center">0</td><td align="center">c34G&#x0003e;T pG12C</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">2.25</td><td align="center">2.59</td><td align="center">1.78</td></tr></tbody></table><table-wrap-foot><p>For quantitative PCR, an inferred copy number &#x02265; 4 defines an amplification of target and an inferred copy number &#x02264; 0.6 defines homozygous deletion. Tumors analyzed by Xba1 50000 SNPs array (Affymetrix) are underlined.</p></table-wrap-foot></table-wrap></sec><sec><title>Relation between cyclin amplification and clinicopathological parameters</title><p>A significant association was found between <italic>CCND1 </italic>amplification and tobacco exposure (p = 0.023) and <italic>TP53 </italic>mutations were linked to <italic>CCNE1 </italic>(p = 0.006), or <italic>CCND1 </italic>(p = 0.048) amplifications (Table <xref ref-type="table" rid="T4">4</xref>). One tumor showed simultaneous amplification of both cyclins.</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Statistical analysis: CCND1, CCNE1, CDKN2A associations with clinico-pathological features and other gene alterations. </p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="2">CDKN2A</td><td align="center">CDKN2A presence of homozygous deletion n (%)</td><td align="center">CDKN2A absence of homozygous deletion n (%)</td><td align="center">p</td></tr></thead><tbody><tr><td align="center">Age</td><td></td><td align="center">62</td><td align="center">62,6</td><td align="center">NS</td></tr><tr><td align="center">Gender</td><td align="center">Women</td><td align="center">6 (12)</td><td align="center">44 (88)</td><td align="center">0,157</td></tr><tr><td></td><td align="center">Men</td><td align="center">2 (4)</td><td align="center">46 (96)</td><td></td></tr><tr><td align="center">Histology</td><td align="center">ADC</td><td align="center">7 (10)</td><td align="center">61 (90)</td><td align="center">0,483</td></tr><tr><td></td><td align="center">LCC</td><td align="center">0 (0)</td><td align="center">6 (100)</td><td></td></tr><tr><td></td><td align="center">SCC</td><td align="center">1 (4)</td><td align="center">23 (96)</td><td></td></tr><tr><td align="center">Tobacco</td><td align="center">Never-smoker</td><td align="center">5 (20)</td><td align="center">20 (80)</td><td align="center">0,012</td></tr><tr><td></td><td align="center">Smoker</td><td align="center">3 (4)</td><td align="center">70 (96)</td><td></td></tr><tr><td></td><td align="center">Mutated</td><td align="center">5 (33)</td><td align="center">10 (67)</td><td></td></tr><tr><td align="center">EGFR</td><td align="center">Non-mutated</td><td align="center">3 (4)</td><td align="center">80 (96)</td><td align="center">0,002</td></tr><tr><td></td><td align="center">Mutated</td><td align="center">1 (5)</td><td align="center">19 (95)</td><td></td></tr><tr><td align="center">KRAS</td><td align="center">Non-mutated</td><td align="center">7 (9)</td><td align="center">71 (91)</td><td align="center">0,563</td></tr><tr><td></td><td align="center">Mutated</td><td align="center">1 (14)</td><td align="center">6 (86)</td><td></td></tr><tr><td align="center">STK11</td><td align="center">Non-mutated</td><td align="center">7 (8)</td><td align="center">84 (92)</td><td align="center">0,46</td></tr><tr><td></td><td align="center">Mutated</td><td align="center">3 (7)</td><td align="center">40 (93)</td><td></td></tr><tr><td align="center">TP53</td><td align="center">Non-mutated</td><td align="center">5 (9)</td><td align="center">50 (91)</td><td align="center">0,704</td></tr><tr><td align="center">AKT-mTOR activation*</td><td align="center">Yes</td><td align="center">7 (29)</td><td align="center">17 (71)</td><td align="center">&#x0003c;0,001</td></tr><tr><td></td><td align="center">No</td><td align="center">1 (1)</td><td align="center">73 (99)</td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="center" colspan="2">CCND1</td><td align="center">Amplification n (%)</td><td align="center">No amplification n (%)</td><td align="center">P</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="center">Age</td><td></td><td align="center">61,8</td><td align="center">63</td><td align="center">NS</td></tr><tr><td align="center">Gender</td><td align="center">Women</td><td align="center">5 (10)</td><td align="center">45 (90)</td><td align="center">0,331</td></tr><tr><td></td><td align="center">Men</td><td align="center">8 (17)</td><td align="center">40 (83)</td><td></td></tr><tr><td align="center">Histology</td><td align="center">ADC</td><td align="center">6 (9)</td><td align="center">62 (91)</td><td align="center">0,079</td></tr><tr><td></td><td align="center">LCC</td><td align="center">2 (33)</td><td align="center">4 (67)</td><td></td></tr><tr><td></td><td align="center">SCC</td><td align="center">5 (21)</td><td align="center">19 (71)</td><td></td></tr><tr><td align="center">Tobacco</td><td align="center">Never-smoker</td><td align="center">0</td><td align="center">25 (100)</td><td align="center">0,023</td></tr><tr><td></td><td align="center">Smoker</td><td align="center">13 (18)</td><td align="center">60 (82)</td><td></td></tr><tr><td align="center">EGFR</td><td align="center">Mutated</td><td align="center">1 (7)</td><td align="center">14 (93)</td><td align="center">0,331</td></tr><tr><td></td><td align="center">Non-mutated</td><td align="center">12 (14)</td><td align="center">71 (86)</td><td></td></tr><tr><td align="center">KRAS</td><td align="center">Mutated</td><td align="center">2 (10)</td><td align="center">18 (90)</td><td align="center">0,629</td></tr><tr><td></td><td align="center">Non-mutated</td><td align="center">11 (14)</td><td align="center">67 (86)</td><td></td></tr><tr><td align="center">STK11</td><td align="center">Mutated</td><td align="center">1 (1)</td><td align="center">6 (99)</td><td align="center">0,934</td></tr><tr><td></td><td align="center">Non-mutated</td><td align="center">12 (13)</td><td align="center">79 (87)</td><td></td></tr><tr><td align="center">TP53</td><td align="center">Mutated</td><td align="center">9 (21)</td><td align="center">34 (79)</td><td align="center">0,048</td></tr><tr><td></td><td align="center">Non-mutated</td><td align="center">4 (7)</td><td align="center">51 (83)</td><td></td></tr><tr><td align="center">AKT-mTOR activation*</td><td align="center">Yes</td><td align="center">2 (8)</td><td align="center">22 (92)</td><td align="center">0,412</td></tr><tr><td></td><td align="center">No</td><td align="center">11 (15)</td><td align="center">63 (85)</td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="center" colspan="2">CCNE1</td><td align="center">Amplification n (%)</td><td align="center">No-amplification n (%)</td><td align="center">P</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="center">Age</td><td></td><td align="center">67</td><td align="center">62,5</td><td align="center">NS</td></tr><tr><td align="center">Gender</td><td align="center">Women</td><td align="center">2 (4)</td><td align="center">47 (96)</td><td align="center">0,371</td></tr><tr><td></td><td align="center">Men</td><td align="center">4 (8)</td><td align="center">45 (92)</td><td></td></tr><tr><td align="center">Histology</td><td align="center">ADC</td><td align="center">2 (3)</td><td align="center">66 (97)</td><td align="center">0,099</td></tr><tr><td></td><td align="center">LCC</td><td align="center">1 (1)</td><td align="center">5 (99)</td><td></td></tr><tr><td></td><td align="center">SCC</td><td align="center">3 (13)</td><td align="center">21 (87)</td><td></td></tr><tr><td align="center">Tobacco</td><td align="center">Never-smoker</td><td align="center">1 (1)</td><td align="center">24 (99)</td><td align="center">0,518</td></tr><tr><td></td><td align="center">Smoker</td><td align="center">5 (17)</td><td align="center">68 (83)</td><td></td></tr><tr><td align="center">EGFR</td><td align="center">Mutated</td><td align="center">1 (1)</td><td align="center">14 (99)</td><td align="center">0,924</td></tr><tr><td></td><td align="center">Non-mutated</td><td align="center">5 (7)</td><td align="center">78 (93)</td><td></td></tr><tr><td align="center">KRAS</td><td align="center">Mutated</td><td align="center">1 (1)</td><td align="center">19 (99)</td><td align="center">0,814</td></tr><tr><td></td><td align="center">Non-mutated</td><td align="center">5 (6)</td><td align="center">73 (94)</td><td></td></tr><tr><td align="center">STK11</td><td align="center">Mutated</td><td align="center">0</td><td align="center">7 (100)</td><td align="center">0,483</td></tr><tr><td></td><td align="center">Non-mutated</td><td align="center">6 (7)</td><td align="center">85 (93)</td><td></td></tr><tr><td align="center">TP53</td><td align="center">Mutated</td><td align="center">6 (15)</td><td align="center">37 (85)</td><td align="center">0,006</td></tr><tr><td></td><td align="center">Non-mutated</td><td align="center">0</td><td align="center">55 (100)</td><td></td></tr><tr><td align="center">AKT-mTOR activation*</td><td align="center">Yes</td><td align="center">2 (8)</td><td align="center">22 (82)</td><td align="center">0,603</td></tr><tr><td></td><td align="center">No</td><td align="center">4 (5)</td><td align="center">70 (85)</td><td></td></tr></tbody></table><table-wrap-foot><p> In this work we called PI3K-AKT-mTOR activated tumors, tumors with either EGFR, PIK3CA, ERBB2 or STK11 mutation*.</p></table-wrap-foot></table-wrap></sec><sec><title>Relation between <italic>CDKN2A </italic>homozygous deletion and clinicopathological parameters</title><p><italic>CDKN2A </italic>homozygous deletions were significantly associated with <italic>EGFR </italic>mutations (p = 0.002) and absence of tobacco exposure (p = 0.012). One tumor had <italic>CDKN2A </italic>homozygous deletion and <italic>CCNE1 </italic>amplification (Table <xref ref-type="table" rid="T4">4</xref>). Three tumors from smokers had <italic>CDKN2A </italic>homozygous deletion, one had a <italic>STK11 </italic>and the other a <italic>PIK3CA </italic>mutation. It suggested that an activation of the EGFR/PI3K/AKT/mTOR pathway could be linked to <italic>CDKN2A </italic>homozygous deletion in lung cancer regardless of smoking status. All together, 8 tumors out of 9 with <italic>CDKN2A </italic>homozygous have EGFR/PI3K/AKT/mTOR pathway alterations.</p></sec></sec><sec><title>Discussion</title><p>In lung cancer, EGFR inhibitors have been shown to be efficient in tumors with activating mutations of the receptor. This molecular alteration defines a subgroup of patients with specific clinicopathological features. The most striking one is the fact that patients are mostly non-smokers. Understanding the carcinogenesis pathway that drives lung carcinogenesis in non-smokers is therefore of major interest. The present work represents the first comparative study of genome wide allelic imbalance between <italic>EGFR </italic>mutated lung ADC and <italic>KRAS </italic>mutated ADC. In our work, <italic>EGFR </italic>mutated tumors are from non-smoking women with ADC, the control group was selected among smoking women with ADC and without <italic>EGFR </italic>mutations. As most of them have <italic>KRAS </italic>mutations, we chose to consider for the SNP array only tumors with <italic>KRAS </italic>mutations in order to have a homogenous control group. Moreover, it was already suggested that <italic>KRAS </italic>and <italic>EGFR </italic>mutations were hallmarks of tobacco and non-tobacco induced lung carcinogenesis [<xref ref-type="bibr" rid="B17">17</xref>]. Different reports showed that SNP array technology provided the opportunity to assess DNA copy number and LOH through the entire genome [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. The overall pattern of alterations seen in this study is reliable with previous lung ADC studies. As already noted, frequent chromosome gains are found at 1q, 5p, 7p/q, 8q and 14q and losses at 6q, 8p, 9p, 13q, 18q and 19p [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. But new regions of homozygous deletion have been found in EGFR mutated tumors especially at 18q involving the DCC gene and a cluster of desmosomal proteins. New regions of focal amplification at 7p and 14q have also been delineated that encodes potential oncogenes [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>Using this technology, we showed that genome wide allelic imbalance patterns are different in tumors from non-smokers when compared to that of smokers. Indeed, more LOH and amplified regions were found in the <italic>EGFR </italic>mutated group when considering either all regions &#x0003e; 5 SNPs or entire chromosome arm losses or amplifications. This fact has already been suggested in a previous work using microsatellite markers and showing that tumors in non-smokers had more alterations than that of smokers [<xref ref-type="bibr" rid="B23">23</xref>]. The mechanisms leading to this increased chromosomal instability is not yet understood. In this series <italic>TP53 </italic>mutations were equally distributed in both groups therefore the impact of TP53 on genome stability cannot be discussed. Other mechanism such as repair defects could be involved in increased chromosomal instability in non-smokers.</p><p>In parallel to DNA assays, RNA expression profiles also demonstrated differences between ADC from smokers when compared with non-smokers [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. In a recent paper dealing with expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung cancer two groups of ADC were individualized, one being a bronchial-type, the other an alveolar-type [<xref ref-type="bibr" rid="B26">26</xref>]. Unsupervised classification failed to detect any specific group of tumors that had <italic>EGFR </italic>mutations but they showed 26 genes preferentially expressed in <italic>EGFR </italic>mutated group. Among them, three genes <italic>EGFR</italic>, <italic>PTK7 </italic>and <italic>HMOX2 </italic>were found in our series located in focal regions of amplifications. Finally, a genetic classification of lung ADC by CGH array showed that <italic>EGFR </italic>mutated tumors could be individualized as a specific cluster [<xref ref-type="bibr" rid="B27">27</xref>]. All together, these results tend to prove that lung ADC in non-smokers forms a distinct disease at least at a molecular point of view. SNP arrays allow the identification of many loci with either LOH or amplification. Some of which may represent background alterations with no specific involvement in the carcinogenesis process. The identification of regions that are critical for tumor cell proliferation is of major importance. In order to go further in the identification of alterations linked to <italic>EGFR </italic>mutations we focused on genes implicated in cell cycle regulation and validated SNP array information on a large series of NSCLC. Previous genome analysis using SNP Arrays also showed <italic>CDKN2A </italic>homozygous deletions and <italic>CCNE1 </italic>amplifications in lung cancers [<xref ref-type="bibr" rid="B12">12</xref>]. We found a link between <italic>CDKN2A </italic>homozygous deletion and the non-smoking status as already suggested by Kraunz et al. [<xref ref-type="bibr" rid="B28">28</xref>]. Moreover, in our series <italic>CDKN2A </italic>deletion was associated with <italic>EGFR </italic>mutation and maybe with an activation of the EGFR/PI3K/AKT/mTOR transduction pathway. Indeed, 7 out of 8 tumors with <italic>CDKN2A </italic>homozygous deletion have <italic>EGFR</italic>, <italic>STK11 </italic>or <italic>PIK3CA </italic>mutations. Activation of this signal transduction pathway can lead to enhance transcription of cell cycle genes as <italic>CCND1 </italic>and it is not surprising that no cyclin amplification was observed in this group. For this group of tumors, it seems that proliferation is under the dependence of an activation of cell cycle through EGFR/PI3K/AKT/mTOR signaling and an inactivation of the cell cycle inhibitor <italic>CDKN2A </italic>preventing cells to down-regulate proliferation. The <italic>CDKN2A </italic>locus at 9p21 encodes two genes, one inhibits CDK4 mediated RB phosphorylation (<italic>CDKN2A/p16</italic>) and the other binds MDM2 leading to TP53 stabilization (<italic>p14/ARF</italic>). qPCR experiments reported here, analyzed homozygous deletions at 9p21 and therefore co-deletion of both genes. A recent paper showed that the p14/ARF protein was frequently down regulated in lung cancers with <italic>EGFR </italic>mutation or in tumors with <italic>ERBB2 </italic>mutations. As in our work, down regulation of the <italic>CDKN2A/p14/ARF </italic>locus could be linked to PI3K/AKT/mTOR activation as both <italic>EGFR </italic>and <italic>ERBB2 </italic>activate this pathway [<xref ref-type="bibr" rid="B29">29</xref>]. Although, regarding our results, it is very surprising that in their experiments, CDKN2A expression measured by immunohistochemistry remained positive when p14/ARF expression was extinguished. It suggested that <italic>p14/ARF </italic>could be down regulated independently of <italic>CDKN2A </italic>by mutation or promoter hypermethylation in <italic>EGFR </italic>mutated tumors. Promoter hypermethylation has indeed been shown to turn off <italic>CDKN2A </italic>locus in cancer but <italic>CDKN2A </italic>hypermethylation was linked to heavy smoking and squamous cell cancer which represents a different subgroup of tumors [<xref ref-type="bibr" rid="B30">30</xref>]. Here we suggest that <italic>CDKN2A/p14/ARF </italic>locus homozygous deletion could be an alternative mechanism to down regulate cell cycle inhibitors in ADC from non-smoking patients. In our series, Illumina GoldenGate Assay for methylation was used to quantify <italic>CDKN2A </italic>methylation, in the 24 tumors analyzed by SNP array. No difference in methylation status was found between EGFR, KRAS mutated tumors and non-tumor tissues (data not shown). Two other papers reported a negative correlation between <italic>EGFR </italic>mutation and <italic>CDKN2A </italic>methylation status in NSCLC [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. Cyclin amplifications were in opposite related to tobacco and associated to <italic>TP53 </italic>mutations. In this case, cell cycle is activated through direct amplification of cyclins and <italic>TP53 </italic>inactivating mutations unable cells to repress proliferation. An association between <italic>CCND1 </italic>and <italic>TP53 </italic>was already suggested by protein expression analysis [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>Although these models are not to generalize since other mechanisms such as mutations epigenetic alteration and protein overexpression can activate oncogene or inactivate tumor suppressor, our work enlightened two different carcinogenesis pathways in NSCLC. One is tobacco independent and driven by CDKN2A inactivation and EGFR mutations, the other is smoking dependent and driven by cyclin amplification and <italic>TP53 </italic>mutation (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Represents two possible models of oncogenic cooperation in smokers </bold>(A) (Cyclin amplification associated with TP53 mutations) and in non-smokers (B) (EGFR mutation associated with CDKN2A homozygous deletion)</p></caption><graphic xlink:href="1755-8794-1-25-2"/></fig></sec><sec><title>Conclusion</title><p>Although this work concerned a limited series of tumors, we focused on a comparative analysis and showed that patterns of genome wide genetic alterations are different between ADC with and without <italic>EGFR </italic>mutation. More alterations and a higher frequency of large alterations (entire chromosome arms deletion or amplification) were found in the <italic>EGFR </italic>mutated group suggesting that carcinogenesis pathways are different. Indeed, for a subset of tumors specific involvement of cell cycle genes were identified and an oncogenic cooperation between <italic>EGFR </italic>mutations and <italic>CDKN2A </italic>homozygous deletion was identified.</p></sec><sec><title>Abbreviations</title><p>ADC: Adenocarcinoma; LCC: Large Cell Carcinoma; SCC: Squamous Cell Carcinoma; BAC: Bronchioloalveolar carcinoma.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>HB: Study design, analysis of the data, redaction of the manuscript. KP: quantitative PCR experiments, sequencing of target genes, analysis of the data. DLC: DNA extraction sequencing of target genes. CD: Study design, Pathological examination of the specimen. MT: quantitative PCR experiments. CH: sequencing of target genes. EF-G: Study design, collection of clinical data associated with tumor specimen. MR: Study design, collection of clinical data associated with tumor specimen. PD: Analysis of the data and redaction of the manuscript. PL-P: Study design, analysis of the data, redaction of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1755-8794/1/25/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Provides a list of probes and primers used in the study for qPCR experiments.</p></caption><media xlink:href="1755-8794-1-25-S1.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>Shows detailed statistical analysis using aCGH package. p was corrected for multiple testing situations. One region at 14q and three regions at 7p show meaningful differences between EGFR mutated and non-mutated tumors.</p></caption><media xlink:href="1755-8794-1-25-S2.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p>Shows regions of focal amplifications analyzed by Xba1 50000 SNPs array (Affymetrix) in EGFR mutated and KRAS mutated tumors independently of statistical differences. Genes, written in bold, have potential or obvious involvement in cell growth. For regions counting more than 10 genes only genes likely to have a role in carcinogenesis are given.</p></caption><media xlink:href="1755-8794-1-25-S3.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p>Shows the comparaison between the copy number estimated by the 50K SNP Array and qPCR.</p></caption><media xlink:href="1755-8794-1-25-S4.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank La Ligue Nationale de Lutte Contre le Cancer, l'Institut National du Cancer (INCA) and le Canc&#x000e9;ropole Ile de France for their support.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer statistics, 2007</article-title><source>CA Cancer J Clin</source><year>2007</year><volume>57</volume><fpage>43</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">17237035</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wakelee</surname><given-names>HA</given-names></name><name><surname>Chang</surname><given-names>ET</given-names></name><name><surname>Gomez</surname><given-names>SL</given-names></name><name><surname>Keegan</surname><given-names>TH</given-names></name><name><surname>Feskanich</surname><given-names>D</given-names></name><name><surname>Clarke</surname><given-names>CA</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name><name><surname>Yong</surname><given-names>LC</given-names></name><name><surname>Kolonel</surname><given-names>LN</given-names></name><name><surname>Gould</surname><given-names>MK</given-names></name><name><surname>West</surname><given-names>DW</given-names></name></person-group><article-title>Lung cancer incidence in never smokers</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">17290054</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2006.07.2983</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahrendt</surname><given-names>SA</given-names></name><name><surname>Decker</surname><given-names>PA</given-names></name><name><surname>Alawi</surname><given-names>EA</given-names></name><name><surname>Zhu</surname><given-names>YR</given-names></name><name><surname>Sanchez-Cespedes</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>SC</given-names></name><name><surname>Haasler</surname><given-names>GB</given-names></name><name><surname>Kajdacsy-Balla</surname><given-names>A</given-names></name><name><surname>Demeure</surname><given-names>MJ</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name></person-group><article-title>Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung</article-title><source>Cancer</source><year>2001</year><volume>92</volume><fpage>1525</fpage><lpage>1530</lpage><pub-id pub-id-type="pmid">11745231</pub-id><pub-id pub-id-type="doi">10.1002/1097-0142(20010915)92:6&#x0003c;1525::AID-CNCR1478&#x0003e;3.0.CO;2-H</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blons</surname><given-names>H</given-names></name><name><surname>Cote</surname><given-names>JF</given-names></name><name><surname>Le Corre</surname><given-names>D</given-names></name><name><surname>Riquet</surname><given-names>M</given-names></name><name><surname>Fabre-Guilevin</surname><given-names>E</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Danel</surname><given-names>C</given-names></name></person-group><article-title>Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation</article-title><source>Am J Surg Pathol</source><year>2006</year><volume>30</volume><fpage>1309</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">17001163</pub-id><pub-id pub-id-type="doi">10.1097/01.pas.0000213285.65907.31</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gealy</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Siegfried</surname><given-names>JM</given-names></name><name><surname>Luketich</surname><given-names>JD</given-names></name><name><surname>Keohavong</surname><given-names>P</given-names></name></person-group><article-title>Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>1999</year><volume>8</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">10207632</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Sordella</surname><given-names>R</given-names></name><name><surname>Gurubhagavatula</surname><given-names>S</given-names></name><name><surname>Okimoto</surname><given-names>RA</given-names></name><name><surname>Brannigan</surname><given-names>BW</given-names></name><name><surname>Harris</surname><given-names>PL</given-names></name><name><surname>Haserlat</surname><given-names>SM</given-names></name><name><surname>Supko</surname><given-names>JG</given-names></name><name><surname>Haluska</surname><given-names>FG</given-names></name><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name></person-group><article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2129</fpage><lpage>2139</lpage><pub-id pub-id-type="pmid">15118073</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa040938</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marchetti</surname><given-names>A</given-names></name><name><surname>Martella</surname><given-names>C</given-names></name><name><surname>Felicioni</surname><given-names>L</given-names></name><name><surname>Barassi</surname><given-names>F</given-names></name><name><surname>Salvatore</surname><given-names>S</given-names></name><name><surname>Chella</surname><given-names>A</given-names></name><name><surname>Camplese</surname><given-names>PP</given-names></name><name><surname>Iarussi</surname><given-names>T</given-names></name><name><surname>Mucilli</surname><given-names>F</given-names></name><name><surname>Mezzetti</surname><given-names>A</given-names></name><name><surname>Cuccurullo</surname><given-names>F</given-names></name><name><surname>Sacco</surname><given-names>R</given-names></name><name><surname>Buttitta</surname><given-names>F</given-names></name></person-group><article-title>EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>857</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">15681531</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.08.043</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paez</surname><given-names>JG</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Tracy</surname><given-names>S</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Herman</surname><given-names>P</given-names></name><name><surname>Kaye</surname><given-names>FJ</given-names></name><name><surname>Lindeman</surname><given-names>N</given-names></name><name><surname>Boggon</surname><given-names>TJ</given-names></name><name><surname>Naoki</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Eck</surname><given-names>MJ</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1497</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">15118125</pub-id><pub-id pub-id-type="doi">10.1126/science.1099314</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alberg</surname><given-names>AJ</given-names></name><name><surname>Samet</surname><given-names>JM</given-names></name></person-group><article-title>Epidemiology of lung cancer</article-title><source>Chest</source><year>2003</year><volume>123</volume><fpage>21S</fpage><lpage>49S</lpage><pub-id pub-id-type="pmid">12527563</pub-id><pub-id pub-id-type="doi">10.1378/chest.123.1_suppl.21S</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Fox</surname><given-names>EA</given-names></name><name><surname>Hochberg</surname><given-names>EP</given-names></name><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Hofer</surname><given-names>MD</given-names></name><name><surname>Descazeaud</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>WH</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays</article-title><source>PLoS Comput Biol</source><year>2006</year><volume>2</volume><fpage>e41</fpage><pub-id pub-id-type="pmid">16699594</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0020041</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Girard</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>TH</given-names></name><name><surname>Minna</surname><given-names>J</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><article-title>High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>2716</fpage><lpage>2726</lpage><pub-id pub-id-type="pmid">15048096</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207329</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>LaFramboise</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Garraway</surname><given-names>L</given-names></name><name><surname>Beheshti</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Naoki</surname><given-names>K</given-names></name><name><surname>Richards</surname><given-names>WG</given-names></name><name><surname>Sugarbaker</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name><name><surname>Girard</surname><given-names>L</given-names></name><name><surname>Minna</surname><given-names>J</given-names></name><name><surname>Christiani</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><article-title>Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>5561</fpage><lpage>5570</lpage><pub-id pub-id-type="pmid">15994928</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4603</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nannya</surname><given-names>Y</given-names></name><name><surname>Sanada</surname><given-names>M</given-names></name><name><surname>Nakazaki</surname><given-names>K</given-names></name><name><surname>Hosoya</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hangaishi</surname><given-names>A</given-names></name><name><surname>Kurokawa</surname><given-names>M</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Bailey</surname><given-names>DK</given-names></name><name><surname>Kennedy</surname><given-names>GC</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name></person-group><article-title>A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>6071</fpage><lpage>6079</lpage><pub-id pub-id-type="pmid">16024607</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0465</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bondi</surname><given-names>J</given-names></name><name><surname>Husdal</surname><given-names>A</given-names></name><name><surname>Bukholm</surname><given-names>G</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name><name><surname>Bakka</surname><given-names>A</given-names></name><name><surname>Bukholm</surname><given-names>IR</given-names></name></person-group><article-title>Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome</article-title><source>J Clin Pathol</source><year>2005</year><volume>58</volume><fpage>509</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">15858123</pub-id><pub-id pub-id-type="doi">10.1136/jcp.2004.020347</pub-id></citation></ref><ref id="B15"><citation citation-type="other"><ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/repository/release1.4/package/Source/"/></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cismasiu</surname><given-names>VB</given-names></name><name><surname>Denes</surname><given-names>SA</given-names></name><name><surname>Reilander</surname><given-names>H</given-names></name><name><surname>Michel</surname><given-names>H</given-names></name><name><surname>Szedlacsek</surname><given-names>SE</given-names></name></person-group><article-title>The MAM (meprin/A5-protein/PTPmu) domain is a homophilic binding site promoting the lateral dimerization of receptor-like protein-tyrosine phosphatase mu</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>26922</fpage><lpage>26931</lpage><pub-id pub-id-type="pmid">15084579</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M313115200</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name></person-group><article-title>Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?</article-title><source>Trends Mol Med</source><year>2004</year><volume>10</volume><fpage>481</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">15464447</pub-id><pub-id pub-id-type="doi">10.1016/j.molmed.2004.08.008</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Greshock</surname><given-names>J</given-names></name><name><surname>Watt</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>S</given-names></name><name><surname>Grigorova</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>KW</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Shapero</surname><given-names>MH</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name></person-group><article-title>High-resolution analysis of DNA copy number using oligonucleotide microarrays</article-title><source>Genome Res</source><year>2004</year><volume>14</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">14762065</pub-id><pub-id pub-id-type="doi">10.1101/gr.2012304</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dutt</surname><given-names>A</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name></person-group><article-title>Single nucleotide polymorphism array analysis of cancer</article-title><source>Curr Opin Oncol</source><year>2007</year><volume>19</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">17133111</pub-id><pub-id pub-id-type="doi">10.1097/CCO.0b013e328011a8c1</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>LaFramboise</surname><given-names>T</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Harrington</surname><given-names>D</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><article-title>Allele-specific amplification in cancer revealed by SNP array analysis</article-title><source>PLoS Comput Biol</source><year>2005</year><volume>1</volume><fpage>e65</fpage><pub-id pub-id-type="pmid">16322765</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0010065</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>L</given-names></name><name><surname>Zochbauer-Muller</surname><given-names>S</given-names></name><name><surname>Virmani</surname><given-names>AK</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name></person-group><article-title>Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>4894</fpage><lpage>4906</lpage><pub-id pub-id-type="pmid">10987304</pub-id></citation></ref><ref id="B22"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Woo</surname><given-names>MS</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Perner</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>WM</given-names></name><name><surname>Province</surname><given-names>MA</given-names></name><name><surname>Kraja</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>LA</given-names></name><name><surname>Shah</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>RK</given-names></name><name><surname>Barletta</surname><given-names>JA</given-names></name><name><surname>Borecki</surname><given-names>IB</given-names></name><name><surname>Broderick</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>AC</given-names></name><name><surname>Chiang</surname><given-names>DY</given-names></name><name><surname>Chirieac</surname><given-names>LR</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Giordano</surname><given-names>T</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Lash</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Lindeman</surname><given-names>N</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Morgan</surname><given-names>MB</given-names></name><name><surname>Nadel</surname><given-names>M</given-names></name><name><surname>Orringer</surname><given-names>MB</given-names></name><name><surname>Osborne</surname><given-names>JR</given-names></name><name><surname>Ozenberger</surname><given-names>B</given-names></name><name><surname>Ramos</surname><given-names>AH</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Rusch</surname><given-names>V</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Shepherd</surname><given-names>F</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Tsao</surname><given-names>MS</given-names></name><name><surname>Twomey</surname><given-names>D</given-names></name><name><surname>Verhaak</surname><given-names>RG</given-names></name><name><surname>Weinstock</surname><given-names>GM</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Yoshizawa</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Zakowski</surname><given-names>MF</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Beer</surname><given-names>DG</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Travis</surname><given-names>WD</given-names></name><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><article-title>Characterizing the cancer genome in lung adenocarcinoma</article-title><source>Nature</source><year>2007</year></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>CA</given-names></name><name><surname>Bueno</surname><given-names>R</given-names></name><name><surname>Borczuk</surname><given-names>AC</given-names></name><name><surname>Caracta</surname><given-names>CF</given-names></name><name><surname>Richards</surname><given-names>WG</given-names></name><name><surname>Sugarbaker</surname><given-names>DJ</given-names></name><name><surname>Brody</surname><given-names>JS</given-names></name></person-group><article-title>Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers</article-title><source>Lung Cancer</source><year>2003</year><volume>39</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">12499090</pub-id><pub-id pub-id-type="doi">10.1016/S0169-5002(02)00384-7</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>A</given-names></name><name><surname>Richards</surname><given-names>WG</given-names></name><name><surname>Staunton</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Monti</surname><given-names>S</given-names></name><name><surname>Vasa</surname><given-names>P</given-names></name><name><surname>Ladd</surname><given-names>C</given-names></name><name><surname>Beheshti</surname><given-names>J</given-names></name><name><surname>Bueno</surname><given-names>R</given-names></name><name><surname>Gillette</surname><given-names>M</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>G</given-names></name><name><surname>Mark</surname><given-names>EJ</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Sugarbaker</surname><given-names>DJ</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><article-title>Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>13790</fpage><lpage>13795</lpage><pub-id pub-id-type="pmid">11707567</pub-id><pub-id pub-id-type="doi">10.1073/pnas.191502998</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>CA</given-names></name><name><surname>Spira</surname><given-names>A</given-names></name><name><surname>Derti</surname><given-names>A</given-names></name><name><surname>DeLisi</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Busch</surname><given-names>S</given-names></name><name><surname>Sahasrabudhe</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Sugarbaker</surname><given-names>D</given-names></name><name><surname>Bueno</surname><given-names>R</given-names></name><name><surname>Richards</surname><given-names>WG</given-names></name><name><surname>Brody</surname><given-names>JS</given-names></name></person-group><article-title>Gene expression in lung adenocarcinomas of smokers and nonsmokers</article-title><source>Am J Respir Cell Mol Biol</source><year>2003</year><volume>29</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">12600827</pub-id><pub-id pub-id-type="doi">10.1165/rcmb.2002-0183RC</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Hanada</surname><given-names>S</given-names></name><name><surname>Kokubu</surname><given-names>A</given-names></name><name><surname>Matsuno</surname><given-names>Y</given-names></name><name><surname>Asamura</surname><given-names>H</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Hirohashi</surname><given-names>S</given-names></name></person-group><article-title>Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma</article-title><source>Cancer Sci</source><year>2007</year><volume>98</volume><fpage>985</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">17459062</pub-id><pub-id pub-id-type="doi">10.1111/j.1349-7006.2007.00483.x</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Uryu</surname><given-names>S</given-names></name><name><surname>Kokubu</surname><given-names>A</given-names></name><name><surname>Hosoda</surname><given-names>F</given-names></name><name><surname>Ohki</surname><given-names>M</given-names></name><name><surname>Sakiyama</surname><given-names>T</given-names></name><name><surname>Matsuno</surname><given-names>Y</given-names></name><name><surname>Tsuchiya</surname><given-names>R</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Imoto</surname><given-names>I</given-names></name><name><surname>Inazawa</surname><given-names>J</given-names></name><name><surname>Hirohashi</surname><given-names>S</given-names></name></person-group><article-title>Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>6177</fpage><lpage>6185</lpage><pub-id pub-id-type="pmid">16144918</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0293</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kraunz</surname><given-names>KS</given-names></name><name><surname>Nelson</surname><given-names>HH</given-names></name><name><surname>Lemos</surname><given-names>M</given-names></name><name><surname>Godleski</surname><given-names>JJ</given-names></name><name><surname>Wiencke</surname><given-names>JK</given-names></name><name><surname>Kelsey</surname><given-names>KT</given-names></name></person-group><article-title>Homozygous deletion of p16(INK4a) and tobacco carcinogen exposure in nonsmall cell lung cancer</article-title><source>Int J Cancer</source><year>2006</year><volume>118</volume><fpage>1364</fpage><lpage>1369</lpage><pub-id pub-id-type="pmid">16184554</pub-id><pub-id pub-id-type="doi">10.1002/ijc.21522</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mounawar</surname><given-names>M</given-names></name><name><surname>Mukeria</surname><given-names>A</given-names></name><name><surname>Le Calvez</surname><given-names>F</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Renard</surname><given-names>H</given-names></name><name><surname>Cortot</surname><given-names>A</given-names></name><name><surname>Bollart</surname><given-names>C</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Brambilla</surname><given-names>E</given-names></name><name><surname>Hainaut</surname><given-names>P</given-names></name></person-group><article-title>Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>5667</fpage><lpage>5672</lpage><pub-id pub-id-type="pmid">17575133</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4229</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakata</surname><given-names>S</given-names></name><name><surname>Sugio</surname><given-names>K</given-names></name><name><surname>Uramoto</surname><given-names>H</given-names></name><name><surname>Oyama</surname><given-names>T</given-names></name><name><surname>Hanagiri</surname><given-names>T</given-names></name><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Yasumoto</surname><given-names>K</given-names></name></person-group><article-title>The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance</article-title><source>Cancer</source><year>2006</year><volume>106</volume><fpage>2190</fpage><lpage>2199</lpage><pub-id pub-id-type="pmid">16598757</pub-id><pub-id pub-id-type="doi">10.1002/cncr.21870</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Iizasa</surname><given-names>T</given-names></name><name><surname>Hiroshima</surname><given-names>K</given-names></name><name><surname>Nakatani</surname><given-names>Y</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name></person-group><article-title>Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer</article-title><source>Cancer</source><year>2006</year><volume>106</volume><fpage>2200</fpage><lpage>2207</lpage><pub-id pub-id-type="pmid">16598760</pub-id><pub-id pub-id-type="doi">10.1002/cncr.21853</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toyooka</surname><given-names>S</given-names></name><name><surname>Tokumo</surname><given-names>M</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Matsuo</surname><given-names>K</given-names></name><name><surname>Asano</surname><given-names>H</given-names></name><name><surname>Tomii</surname><given-names>K</given-names></name><name><surname>Ichihara</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Aoe</surname><given-names>M</given-names></name><name><surname>Date</surname><given-names>H</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name></person-group><article-title>Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>1371</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">16452191</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2625</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mishina</surname><given-names>T</given-names></name><name><surname>Dosaka-Akita</surname><given-names>H</given-names></name><name><surname>Kinoshita</surname><given-names>I</given-names></name><name><surname>Hommura</surname><given-names>F</given-names></name><name><surname>Morikawa</surname><given-names>T</given-names></name><name><surname>Katoh</surname><given-names>H</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name></person-group><article-title>Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome</article-title><source>Br J Cancer</source><year>1999</year><volume>80</volume><fpage>1289</fpage><lpage>1295</lpage><pub-id pub-id-type="pmid">10376986</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6690500</pub-id></citation></ref></ref-list></back></article> 